Precigen (PGEN) Share-based Compensation (2012 - 2026)
Precigen (PGEN) posted quarterly Share-based Compensation of $146000.0 for Q1 2026, down 94.55% year-over-year from $2.7 million in Q1 2025, and down 93.25% quarter-over-quarter from $2.2 million in Q4 2025.
Analysis
Precigen (PGEN) Share-based Compensation (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Share-based Compensation for 15 consecutive years, with $146000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 94.55% year-over-year to $146000.0; the TTM figure through Mar 2026 stood at $8.3 million (down 12.88% YoY), while the FY2025 annual figure was $10.9 million, up 14.73% from the prior year.
- Share-based Compensation fell to $146000.0 in Q1 2026 per PGEN's latest filing, from $2.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.9 million in Q3 2025 and bottomed at -$7.6 million in Q4 2023.
- Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $2.3 million in 2023.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 445.07% — and 2024, when it surged 186.47%.
- Precigen's Share-based Compensation stood at $2.2 million in 2022, then sank by 445.07% to -$7.6 million in 2023, then surged by 137.57% to $2.9 million in 2024, then decreased by 24.5% to $2.2 million in 2025, then sank by 93.25% to $146000.0 in 2026.
- Business Quant data shows PGEN's Share-based Compensation at $146000.0 in Q1 2026, $2.2 million in Q4 2025, and $6.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 3.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 2.68 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 2.26 Mn |
| Sep 30, 2023 | 2.31 Mn |
| Jun 30, 2023 | 2.19 Mn |
| Mar 31, 2023 | 3.13 Mn |
| Dec 31, 2022 | 2.21 Mn |
| Sep 30, 2022 | 2.13 Mn |
| Jun 30, 2022 | 2.31 Mn |
| Mar 31, 2022 | 3.56 Mn |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | 2.49 Mn |